Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/37089
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Samad N. | en |
dc.contributor.author | Wong J. | en |
dc.date.accessioned | 2021-05-14T12:36:19Z | en |
dc.date.available | 2021-05-14T12:36:19Z | en |
dc.date.copyright | 2018 | en |
dc.date.created | 20180907 | en |
dc.date.issued | 2018-09-07 | en |
dc.identifier.citation | BMJ Case Reports. 2018 (no pagination), 2018. Article Number: 225745. Date of Publication: 2018. | en |
dc.identifier.issn | 1757-790X (electronic) | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/37089 | en |
dc.description.abstract | AMPA receptor (AMPAR) antibodies are a group of recently discovered antibodies which target the neuronal synaptic proteins causing B-cell (immune) mediated neuronal damage, resulting in various neurologic syndromes depending on the area of central nervous system involvement. These syndromes are mostly reversible if treated early. Tumour association has been reported in up to 60% of cases in the most recent case series with lung, breast, ovarian cancers and thymomas being the most commonly associated malignancies with these antibodies. We present here the first case of AMPAR encephalitis associated with medullary thyroid cancer. Our patient presented with cognitive dysfunction and behavioural changes over a period of 3 weeks, with a full recovery after starting immunotherapy, once the diagnosis of AMPAR limbic encephalitis was established. This case highlights the importance of early diagnosis and management of AMPAR encephalitis as these patients respond well to immunotherapy and can have an almost complete recovery.Copyright © 2018 BMJ Publishing Group Limited. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | BMJ Publishing Group (E-mail: subscriptions@bmjgroup.com) | en |
dc.relation.ispartof | BMJ Case Reports | en |
dc.title | Anti-AMPA receptor encephalitis associated with Medullary thyroid cancer. | en |
dc.type | Article | en |
dc.type.studyortrial | Case series or case report | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1136/bcr-2018-225745 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 30150348 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30150348] | en |
dc.identifier.source | 623686804 | en |
dc.identifier.institution | (Samad, Wong) Department of Endocrinology, Monash Health, Melbourne, VIC, Australia | en |
dc.description.address | N. Samad, Department of Endocrinology, Monash Health, Melbourne, VIC, Australia. E-mail: navira7@hotmail.com | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2019 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | brainstem/cerebellum cancer-see oncology endocrine cancer immunology thyroid disease | en |
dc.identifier.authoremail | Samad N.; navira7@hotmail.com | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.